oxytetracycline--anhydrous has been researched along with Lung-Neoplasms* in 6 studies
1 trial(s) available for oxytetracycline--anhydrous and Lung-Neoplasms
Article | Year |
---|---|
Rapid pleurodesis in symptomatic malignant pleural effusion.
The objective of the study was to see whether a rapid method of pleurodesis was superior to the standard protocol in patients with symptomatic malignant pleural effusion.. Between January 2000 and February 2003, a prospective randomised trial was carried out in a sequential sample of 27 patients with malignant pleural effusions documented cytopathologically. Twelve patients were allocated to group 1 (standard protocol) and 15 to group 2 (new protocol). A small-bore catheter (12 Fr) and oxytetracycline (35 mg/kg of body weight) were used in both groups. In group 1, patients had drainage until radiological evidence of lung re-expansion was obtained and the amount of fluid drained was less than 150 ml/day, before oxytetracycline was instilled. The catheter was removed when the amount of fluid drained after instillation was less than 150 ml/day. In group 2, patients had the oxytetracycline instilled in a fractionated-dose manner following frequent aspirations at 6h intervals. The catheter was removed when the total amount of fluid drained after instillation of the oxytetracycline [OT] was less than 150 ml/last three aspirations. Response was evaluated at 1, 3 and 6 months after pleurodesis.. There was no statistically significant difference in the demographic features, site of the primary tumour, disease characteristics, and response rates in any evaluation period in both groups (P>0.05). However, the number of days of drainage and hospitalisation, and the cost were significantly lower in the second group (P<0.001).. This new pleurodesis method provided shorter hospital stay resulting in superior cost-effectiveness and palliation without sacrificing the efficacy of pleurodesis. Topics: Adult; Aged; Breast Neoplasms; Drainage; Female; Glucose; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Oxytetracycline; Palliative Care; Pleural Effusion, Malignant; Pleurodesis; Prospective Studies; Treatment Outcome | 2005 |
5 other study(ies) available for oxytetracycline--anhydrous and Lung-Neoplasms
Article | Year |
---|---|
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite elec
In this present work we made a novel, fast, selective and sensitive electrochemical genobiosensor to detection of EGFR exon 21 point mutation based on two step electropolymerization of Ni(II)-oxytetracycline conducting metallopolymer nanoparticles (Ni-OTC NPs) on the surface of pencil graphite electrode (PGE) which was modified by reduced graphene oxide/carboxyl functionalized ordered mesoporous carbon (rGO/f-OMC) nanocomposite. ssDNA capture probe with amine groups at the5' end which applied as recognition element was immobilized on the rGO/f-OMC/PGE surface via the strong amide bond. Ni-OTC metallopolymer NPs were electropolymerized to rGO/ssDNA-OMC/PGE surface and then hybridization fallows through the peak current change in differential pulse voltammetry (DPV) using Ni-OTC NPs as a redox label. The biosensor was characterized by field emission scanning electron microscopy (FE-SEM), X-ray diffraction (XRD), FT-IR spectroscopy, energy dispersive X-ray spectroscopy (EDX), cyclic voltammetry and Nitrogen adsorption-desorption analysis. The Ni-OTC current response verified only the complementary sequence indicating a significant reduction current signal in comparison to single point mismatched and non-complementary and sequences. Under optimal conditions, the prepared biosensor showed long-term stability (21 days) with a wide linear range from 0.1 µM to 3 µM with high sensitivity (0.0188 mA/µM) and low detection limit (120 nM). Topics: Biomarkers, Tumor; Biosensing Techniques; Carbon; DNA Probes; Electrochemical Techniques; Electrodes; ErbB Receptors; Exons; Graphite; Humans; Immobilized Nucleic Acids; Limit of Detection; Lung Neoplasms; Nanoparticles; Nucleic Acid Hybridization; Oxidation-Reduction; Oxides; Oxytetracycline; Point Mutation | 2018 |
Bronchial pulmonary disease associated with tuberculous lymph nodes.
Topics: Adult; Aged; Antitubercular Agents; Carcinoma, Bronchogenic; Diagnosis, Differential; Female; Humans; Hungary; Lung Neoplasms; Male; Middle Aged; Oxytetracycline; Radiography; Tomography; Tuberculosis, Lymph Node; Tuberculosis, Pulmonary | 1968 |
[PREVENTION AND TREATMENT OF PLEURAL EMPYEMA AND BRONCHIAL FISTULAE FOLLOWING PNEUMONECTOMY].
Topics: Ascorbic Acid; Bronchial Fistula; Bronchiectasis; Empyema; Empyema, Pleural; Humans; Lung Abscess; Lung Neoplasms; Oxytetracycline; Penicillins; Pneumonectomy; Postoperative Complications; Pulmonary Fibrosis; Punctures; Streptomycin; Thiamine | 1963 |
[ESOPHAGITIS CAUSED BY CANDIDA ALBICANS].
Topics: Candida albicans; Candidiasis; Candidiasis, Oral; Deglutition Disorders; Esophagitis; Esophagoscopy; Humans; Lung Neoplasms; Nystatin; Oxytetracycline; Penicillins; Speech Disorders; Vocal Cord Paralysis | 1963 |
Terramycin for nongonococcic urethritis and Reiter's disease.
Topics: Arthritis, Reactive; Humans; Lung Neoplasms; Oxytetracycline; Urethritis | 1952 |